Fortis Healthcare Limited has informed the Exchange regarding a press release dated August 06, 2025, titled "press release and earnings presentation for the quarter ended on June 30, 2025.".
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Midcap 150 and 3.2 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fortis Healthcare reported strong Q1 FY26 results with consolidated revenue at INR 2,167 Cr, up 16.6% year-on-year, driven by an 18.6% growth in the hospital business (INR 1,838 Cr) and a 6.3% rise in diagnostics (INR 329 Cr net). Operating EBITDA surged 43.2% to INR 491 Cr, with margins expanding sharply from 18.4% to 22.6%, helped by higher ARPOB (INR 2.65 Cr), a 200 bps rise in occupancy to 69%, and international patient revenue growing 21%. Profit after tax (post minority interest) jumped 56.8% to INR 260 Cr, with EPS at INR 3.45 versus INR 2.20, aided by an exceptional gain of INR 12.6 Cr from reversal of impairment in an associate. Net debt rose to INR 1,869 Cr (debt-to-EBITDA of 0.92x) due to recent acquisitions, including the buyout of the PE stake in Agilus Diagnostics and the Fortis brand.
Strong beat on margins and profitability signals robust operating leverage and pricing power, likely to be viewed positively by investors; however, the higher debt load from recent acquisitions is a near-term watchpoint even though leverage remains comfortable at 0.92x EBITDA.